Cardio Diagnostics Holdings, Inc. SEC filings CDIO
Cardio Diagnostics Holdings, Inc. has 295 filings in SEC EDGAR's recent list, going back to Jul 20, 2021. Its latest annual report, Form ARS, was filed on Jul 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 18, 2026 (shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B3 | Prospectus | Sep 23, 2025 | — |
| POS AM | Post-effective amendment no. 1 | Sep 16, 2025 | — |
| 424B3 | Prospectus | Sep 12, 2025 | — |
| POS AM | Post-effective amendment no. 3 | Sep 5, 2025 | — |
| S-8 | Employee stock plan registration | Apr 8, 2025 | — |
| 424B3 | Prospectus | Mar 25, 2025 | — |
| 424B3 | Prospectus | Mar 25, 2025 | — |
| 424B5 | Prospectus supplement | Feb 14, 2025 | — |
| S-3 | Shelf registration | Feb 7, 2025 | — |
| 424B3 | Prospectus | Dec 3, 2024 | — |
| S-1 | Registration statement | Nov 22, 2024 | — |
| POS AM | Post effective amendment no. 2 | Aug 30, 2024 | — |
| S-8 | Employee stock plan registration | Apr 26, 2024 | — |
| 424B3 | Prospectus | Apr 2, 2024 | — |
| 424B5 | Prospectus supplement | Feb 1, 2024 | — |
| S-3 | Shelf registration | Jan 26, 2024 | — |
| 424B3 | Prospectus | May 15, 2023 | — |
| 424B3 | Prospectus | May 15, 2023 | — |
| 424B3 | Prospectus | May 1, 2023 | — |
| POS AM | Post-effective amendment no 1 to form s-1 | Apr 24, 2023 | — |
| 424B3 | Prospectus | Apr 11, 2023 | — |
| S-1 | Registration statement | Apr 5, 2023 | — |
| 424B3 | Prospectus | Mar 31, 2023 | — |
| S-8 | Employee stock plan registration | Mar 22, 2023 | — |
| 424B3 | Prospectus | Jan 25, 2023 | — |
| S-1/A | Amended registration statement | Jan 13, 2023 | — |
| S-1/A | Amended registration statement | Dec 27, 2022 | — |
| S-1 | Registration statement | Dec 12, 2022 | — |
| 424B3 | Prospectus | Oct 7, 2022 | — |
| S-4/A | Form s-4/a | Oct 5, 2022 | — |
| S-4/A | Form s-4/a | Oct 4, 2022 | — |
| S-4/A | Form s-4/a | Sep 15, 2022 | — |
| S-4/A | Form s-4 amendment no. 2 | Aug 23, 2022 | — |
| S-4/A | Form s-4/a1 | Jul 27, 2022 | — |
| S-4/A | Form s-4/a1 | Jul 25, 2022 | — |
| S-4 | Registration for a merger or exchange | May 31, 2022 | — |
| 424B4 | Prospectus | Nov 24, 2021 | — |
| S-1/A | Amended registration statement | Nov 17, 2021 | — |
| S-1/A | Amended registration statement | Nov 10, 2021 | — |
| S-1 | Registration statement | Oct 19, 2021 | — |
Showing 40 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- CDIO (Nasdaq), CDIOW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Chicago, IL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1870144
- Former names
- Mana Capital Acquisition Corp. (until Oct 26, 2022)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.